Different doses or strenghts? [General Sta­tis­tics]

posted by kumarnaidu – Mumbai, India, 2013-11-21 15:00 (4589 d 20:36 ago) – Posting: # 11935
Views: 10,456

Hi all,
I got one protocol for review. In that they have given some different design which I want to share with you.
They are having two cohorts. In cohort 1 15 patients will receive T (5 subjects in each dose category) and 15 will receive R
T1, T2 and T3 are different doses. In Cohort 2 - Subject received T in cohort 1 will receive R and Subject received R will receive T (T1 or T2 or T3 based on some set criteria )

Cohort 1 (n = 15)
T1 (n1 = 5)
T2 (n2 = 5)
T3 (n3 = 5)
R (n = 15)

Cohort 2 (n = 15)
R(n = 15)


T1 or T2 or T3 (n = 15)

Bioequivalence will be evaluated in cohort 2. And cohort one will be used for dose identification. According to me we need to use parallel design here for analysis in cohort 2 but what about period and sequence effect.:confused:

Kumar Naidu

Complete thread:

UA Flag
Activity
 Admin contact
23,654 posts in 4,992 threads, 1,571 registered users;
138 visitors (0 registered, 138 guests [including 24 identified bots]).
Forum time: 12:37 CEST (Europe/Vienna)

Always listen to experts.
They’ll tell you what can’t be done and why.
Then do it.    Robert A. Heinlein

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5